releases: http://www.murphy.senate.gov/newsroom/press-releases/murphy-highlights-biohaven-pharmaceuticals-as-murphys-innovator-of-the-month
Data license: MIT · Data source: dwillis/congress-press
This data as json
| url | title | date | year | month | party | chamber | state | member_name | bioguide_id | domain | scraper | source | date_source | text | has_text | collected_at | updated_at |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| http://www.murphy.senate.gov/newsroom/press-releases/murphy-highlights-biohaven-pharmaceuticals-as-murphys-innovator-of-the-month | MURPHY HIGHLIGHTS BIOHAVEN PHARMACEUTICALS AS MURPHYS INNOVATOR OF THE MONTH | 2019-12-30 | 2019 | 2019-12 | Democrat | House | CT | Christopher Murphy | M001169 | www.murphy.senate.gov | legacy | MURPHY HIGHLIGHTS BIOHAVEN PHARMACEUTICALS AS MURPHY'S INNOVATOR OF THE MONTH Monday, December 30, 2019 HARTFORDU.S. Senator Chris Murphy (D-Conn.)announced on Monday that New Haven innovator Biohaven Pharmaceuticals has been named Innovator of the Month. Founded in 2013, Biohaven is arapidly growingcompany focused on neurological-innovation and developing products that address several of the most disabling and devastating neurological disorders, such as migraines, Alzheimer's disease, and anxiety. The company was created to fill what the founders saw as a void in neurology research in the pharmaceutical industry. This is Connecticut innovation at its best. Migraines can be a nightmare and hamper people's ability to function, and Biohaven is leading the way in finding an innovative cure. I'm proud to highlight Biohaven as this month's innovator and encourage investment in treating neurological conditions. I look forward to watching this company continue to grow right here in Connecticut,said Murphy. Vlad Coric, M.D., CEO of Biohaven said,Biohavenisgrateful to Senator Murphy for this recognition and for his strong commitment to supporting innovation toimprove lives andstimulate economic development.Biohavenhasthrivedin theentrepreneurial spirit and strong sense of community herein New Haven, Connecticut.Our goal atBiohavenwas to create an organization that is focused on unmetmedicalneedsand add value for our patients and shareholders while maintaining an efficient and high performing culture. New Haven has beenan ideal location forBiohavengiven its proximity to Yale and highly skilled pharmaceutical talent that sits in the geographic corridor between New York and Boston. Biohavencurrently is seekingFood and Drug Administrationapproval forits first medicine,rimegepant, acalcitoningene-relatedpeptide (CGRP) antagonist that targets the body's neurotransmitter that is the root cause of a migraine headache.Migraines are a leading cause of disability worldwide andBiohaven'sdata published in theNew England Journal of MedicineandThe Lancetshow thatrimegepantworksfor many patientswithin minutes,restores normal functioningandits effectcanlastfortwo days after a single dose. Biohaven'sportfolio also includes a widepipelineof innovative late-stage product candidates includingtroriluzole, a glutamate modulator being studied for the treatmentof mild to moderate Alzheimer's disease(AD), andverdiperstat, a myeloperoxidase inhibitor being studied for multiple neurodegenerative disorders. The company recently received encouraging news thatitsstudyoftroriluzolein ADpassed an interim futility analysis after the first 100 patients completed 6 months of treatment. Biohavenstarted smallwith only a few employeesin the back office of a clinicandwas initially foundeduponintellectual property related to Dr.Coric'swork on glutamate modulating agents licensed from Yale University.Biohavenwent public in 2017 and their common sharesarelisted on the New York Stock Exchange traded under the tickersymbolBHVN.Biohavenhas grown to over 600 employees andhas raised over $1.1 billion to funditsresearch and developmentactivities.Biohavenhas established an impressive presence in New Haven byrenovating a building just off the Yale University campus in the heart of theNew Havenfinancial district. Murphy believes entrepreneurship and innovation are the building blocks for a strong economy. In the U.S. Senate, he has introduced two bipartisan pieces of legislation to incentivize angel investors to put more money into startup companies the Angel Tax Credit Actand theHelping Angels Lead Our Startups (HALOS) Act.Startup companies create an average of 2 million jobs each year. ### | 1 | 2026-03-30T12:14:52Z | 2026-03-30T12:14:52Z |